13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
27 檔
13.0%
As reported in its official Q1 2024 Form 13F filing, Tri Locum Partners LP's tracked investment portfolio stood at $813.2M with 27 total positions.
During Q1 2024, Tri Locum Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, Avadel Pharmaceuticals PLC ADR, SILKUSD) accounted for 13.0% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 10.84% | -1.21% | +23.51% | |
| 2 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 6.97% | — | +41.62% | |
| 3 | SILKUSD | Silk Road Medical Inc | Stock-Other | 6.88% | — | — | |
| 4 | NTRA | Natera Inc | Stock-Healthcare | 6.03% | — | +34.03% | |
| 5 | ASND | Ascendis Pharma A/S | Stock-Other | 5.91% | -8.20% | EXIT | |
| 6 | LEGN | Legend Biotech Corp-adr | Stock-Other | 5.52% | — | +177.62% | |
| 7 | MRK | Merck & Co. Inc. | Stock-Healthcare | 5.45% | — | — | |
| 8 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 5.16% | +4.23% | — | |
| 9 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.94% | -3.08% | +109.04% | |
| 10 | BAX | Baxter International Inc | Stock-Healthcare | 4.71% | — | — | |
| 11 | ✓ | Merus N V | Stock-Other | 4.47% | — | — | |
| 12 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 4.01% | — | — | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.82% | +1.51% | +15.71% | |
| 14 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.10% | — | -8.02% | |
| 15 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.86% | — | -46.50% | |
| 16 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.84% | +5.13% | -21.44% | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.25% | — | -57.19% | |
| 18 | EXK | Exact Sciences CORP | Stock-Materials | 2.16% | — | — | |
| 19 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 2.11% | — | — | |
| 20 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.80% | — | -31.94% | |
| 21 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.76% | — | — | |
| 22 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 1.66% | — | — | |
| 23 | ARCT | Arcturus Therapeutics Holdin | Stock-Other | 1.63% | — | +25.76% | |
| 24 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.55% | — | — | |
| 25 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.24% | — | — | |
| 26 | ISREUR | Isoray Inc | Stock-Other | 0.32% | — | — | |
| 27 | ✓ | Femasys Inc | Stock-Other | 0.02% | — | -15.34% |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 27 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Tri Locum Partners LP's top holdings by market value included TEVA (10.8%)、Avadel Pharmaceuticals PLC ADR (7.0%)、SILKUSD (6.9%). The largest single position, TEVA, represented 10.8% of total portfolio value.
In Q1 2024, Tri Locum Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.